LuaBio ApS

Description of key activities of the companyThe Company develops, scales, and commercialises industrial biotechnology platforms for the conversion of CO2 and other single-carbon industrial waste streams into value-added products. Its principal activities include technology and process development, and the deployment of modular manufacturing facilities and solutions for industrial customers.

Significant changes in the company's activities and financial mattersThe gross profit for the year totals DKK 4.367 thousand against DKK 7.574 thousand last year. Profit or loss from ordinary activities after tax totals DKK -34.022 thousand against DKK -7.413 thousand last year. In light of the below, Management considers the result for the year satisfactory.

During 2025, the Company progressed its strategic expansion through the establishment of its Texas subsidiary and the build-out of the TX-1 plant. In the first half of 2026, Luabio continued executing this development plan, including completion of the structural and mechanical construction of TXS-1. These activities reflect the Company’s continued transition from technology development to industrial implementation and commercial scale-up.

Supporting the next phase of growth and the continued execution of its development roadmap, the Company may in the future look to secure additional liquidity via external financing, especially given the strong investor interest and current growth trajectory.

Events occurring after the end of the financial year

No events have occurred after the balance sheet date of material importance to the annual report for 2025.

10.Contractual obligations and contingencies, etc.

Contractual obligations and contingent liabilitiesLease liabilities:

The company has entered into operational leases with an average annual lease payment of DKK 1.270 thousand. The leases have 41 months to maturity and total outstanding lease payments total DKK 4.337 thousand.